Form D · Biotechnology

Quanta Therapeutics, Inc.

South San Francisco, CA · CIK 0001891891

Offering snapshot reported Jun 24, 2026 · SEC filing

Reported sold: $76.2M
Investors reported: 17
Minimum accepted: $0
First sale: May 10, 2023

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$50,685,368 → $76,192,272
Reported investors13 → 17

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jun 24, 2026	Amendment	$76,192,272	$25,506,904vs May 25, 2023	17	SEC filing
May 25, 2023	Initial	$50,685,368	No comparison	13	SEC filing
Feb 17, 2023	Initial	$29,999,993	No comparison	9	SEC filing
Nov 3, 2021	Initial	$40,152,323	No comparison	10	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-482575

Source: Form D, filed Jun 24, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Leonardo Faoro	Executive
Maria Fardis	Director
Arjun Goyal	Director
Ying Huang	Director
Rajul Jain	Director
Maha Katabi	Director
Derek Metzger	Executive
Perry Nisen	Director, Executive
Cameron Pitt	Director, Executive
Samuel Saks	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

Two Tower Place, Floor 17
South San Francisco, CA, 94080